No information is available on gilteritinib during breastfeeding. It is 94% bound to plasma proteins, so amounts in milk are likely to be low; however, it has a long half-life of about 113 hours. The manufacturer recommends that breastfeeding be discontinued during gilteritinib therapy and for 2 months after the last dose.
关于吉列替尼在母乳喂养期间的信息尚无可用资料。它与血浆蛋白的结合率为94%，因此乳汁中的含量可能较低；然而，它的半衰期很长，约为113小时。制造商建议在吉列替尼治疗期间及最后一剂后2个月内停止母乳喂养。
